Harrow (HROW) vs OPKO Health (OPK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OPKO Health (OPK) has outperformed Harrow (HROW) over the past year, gaining 18.9% versus a loss of 21.8%. Over five years, HROW leads with a +196.1% price change compared with -62.0% for OPK. OPKO Health is the larger company by market cap ($1.17 billion vs $1.14 billion), about 1.0 times the size, while Harrow is growing revenue faster (+36.4% vs -14.9%).
Harrow converts more of its revenue into profit, with a net margin of -1.9% versus -37.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | OPK |
|---|---|---|
| Share price | $30.41 | $1.57 |
| Market cap | $1.14B | $1.17B |
| 1-day change | -5.35% | -2.48% |
| YTD return | -37.94% | +24.60% |
| 1-year return | -21.85% | +18.94% |
| 5-year return | +196.11% | -61.99% |
| Forward P/E | 16.26 | — |
| EPS (TTM) | $-0.76 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $272.30M | $606.88M |
| Revenue growth (YoY) | +36.41% | -14.90% |
| Net income (latest FY) | $-5.14M | $-225.68M |
| Gross margin | 75.05% | 33.93% |
| Operating margin | 11.21% | -19.35% |
| Net margin | -1.89% | -37.19% |
| 52-week high | $54.85 | $1.86 |
| 52-week low | $25.76 | $0.98 |
| Distance from 52-week high | -44.56% | -15.59% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +104.70% | +164.33% |
| Average volume | 626.20K | 3.83M |
| Shares outstanding | 37.53M | 742.51M |
| Employees | 373 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OPK has outperformed HROW by 40.8 percentage points over the past year.
- Harrow is more profitable, keeping -1.9 cents of every revenue dollar as net income versus -37.2 cents for OPKO Health.
- Harrow grew revenue faster in its latest fiscal year (+36.41% vs -14.90%).
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About OPKO Health
OPK stock →OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,275 employees
HROW vs OPK FAQ
Which is bigger, Harrow or OPKO Health?
OPKO Health (OPK) is larger, with a market capitalization of $1.17B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, HROW or OPK?
OPK returned +18.94% over the past 12 months, compared with -21.85% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and OPKO Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.